Aminoalkylindoles (AAIs) are a family of cannabinergic compound that act as a cannabinoid receptor agonist. They were invented by pharmaceutical company Sterling-Winthrop in the early 1990s as potential non-steroidal anti-inflammatory agents.[1]


Aminoalkylindole are now commonly found in synthetic cannabis designer drugs.[2]

In the United States, the DEA added the aminoalkylindole JWH-200 to Schedule I of the Controlled Substances Act on 1 March 2011 for 12 months.[2][3]


  1. Emmanuel S. Onaivi (2006). Marijuana and Cannabinoid Research: Methods and Protocols. Springer. pp. 128–. ISBN 978-1-59259-999-8.
  2. 1 2 "Synthetic Cannabinoids". American Association for Clinical Chemistry. 2013-02-01. Retrieved 2013-11-17.
  3. "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I". Federal Register. 2011-03-01. Retrieved 2013-11-17.

External links

This article is issued from Wikipedia - version of the 10/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.